News and Events

Chief Scientific Officer, Associate Professor Sara Mangsbo, presented some of the latest data demonstrating progress in the development of the ADAC technology platform for precision cancer immunotherapy.

Research to be supported by Cancerfonden, one of Sweden’s largest financiers of cancer research

Joacim Elmén appointed as Director, CMC

Agreement covers Cell Line Development for a novel bi-specific therapeutic mAb

Dr. Sara Mangsbo acknowledged for entrepreneurship and her contribution to Swedish life science industry

Niclas Stiernholm elected as Chairman of the Board

Appoints Lindvi Gudmunsdotter as Director, Non-Clinical Development

CD40 agonistic, bispecific antibody candidates developed using ADAC technology ensure T-cell activation

New data demonstrates proof of concept for ADAC technology platform

Efforts now focus on bringing first candidate to clinical trials and further development of ADAC technology platform

Swedish immuno-oncology newcomer STRIKE Pharma raises SEK 10 million for development of individualized solid tumour therapy.

STRIKE Pharma appoints industry veteran Mårten Winge as new CEO